Key Takeaways Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease. The drug maker reported Kisqali along with endocrine therapy (ET) reduced the risk of recurrence in the test group by nearly 30% compared to ET alone. Novartis expects the FDA to decide on approval of the treatment this quarter. American depositary receipts (ADRs) of Novartis (NVS) gained Monday as new research showed the company's breast cancer treatment, Kisqali, produced longer ...